{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:37:07Z","timestamp":1765280227594},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:00:00Z","timestamp":1605916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:00:00Z","timestamp":1605916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1245\/s10434-020-09366-w","type":"journal-article","created":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T21:02:27Z","timestamp":1605992547000},"page":"3637-3645","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of BRCA1\/2 Mutations on the Efficacy of Secondary Cytoreductive Surgery"],"prefix":"10.1245","volume":"28","author":[{"given":"Felipe Leonardo","family":"Estati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafaela","family":"Pirolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviane Teixeira Loiola","family":"de Alencar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana Regina Gon\u00e7alves","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Nirvana","family":"Formiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovana Tardin","family":"Torrezan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirce Maria","family":"Carraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Paiva Gadelha","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glauco","family":"Baiocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre Andr\u00e9 Balieiro Anast\u00e1cio","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,21]]},"reference":[{"issue":"1","key":"9366_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590","journal-title":"CA Cancer J Clin."},{"key":"9366_CR2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21456","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018. https:\/\/doi.org\/10.3322\/caac.21456","journal-title":"CA Cancer J Clin."},{"issue":"12","key":"9366_CR3","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1093\/annonc\/mdt406","volume":"24","author":"FA Raja","year":"2013","unstructured":"Raja FA, Counsell N, Colombo N, et al. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. Ann Oncol. 2013;24(12):3028\u20133034. https:\/\/doi.org\/10.1093\/annonc\/mdt406","journal-title":"Ann Oncol."},{"issue":"17","key":"9366_CR4","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank S V., Goff BA, et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039\u20132045. https:\/\/doi.org\/10.1200\/jco.2012.42.0505","journal-title":"J Clin Oncol."},{"issue":"6","key":"9366_CR5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","volume":"18","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel\u2013carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779\u2013791. https:\/\/doi.org\/10.1016\/s1470-2045(17)30279-6","journal-title":"Lancet Oncol."},{"issue":"22","key":"9366_CR6","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154\u20132164. https:\/\/doi.org\/10.1056\/nejmoa1611310","journal-title":"N Engl J Med."},{"key":"9366_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70228-1","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014. https:\/\/doi.org\/10.1016\/s1470-2045(14)70228-1","journal-title":"Lancet Oncol."},{"issue":"10106","key":"9366_CR8","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949\u20131961. https:\/\/doi.org\/10.1016\/s0140-6736(17)32440-6","journal-title":"Lancet."},{"key":"9366_CR9","doi-asserted-by":"publisher","unstructured":"Du Bois A, Vergote I, Ferron G, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20. J Clin Oncol. 2017;35(15_suppl):5501. https:\/\/doi.org\/10.1200\/jco.2017.35.15_suppl.5501","DOI":"10.1200\/jco.2017.35.15_suppl.5501"},{"issue":"20","key":"9366_CR10","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Spirtos NM, Enserro D, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019;381(20):1929\u20131939. https:\/\/doi.org\/10.1056\/nejmoa1902626","journal-title":"N Engl J Med."},{"key":"9366_CR11","doi-asserted-by":"publisher","first-page":"6000","DOI":"10.1200\/JCO.2020.38.15_suppl.6000","volume":"38","author":"A Bois","year":"2020","unstructured":"Bois A, Sehouli J, Ferron G, et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III\/ENGOT-ov20. J Clin Oncol. 2020;38:6000. https:\/\/doi.org\/10.1200\/jco.2020.38.15_suppl.6000","journal-title":"J Clin Oncol."},{"key":"9366_CR12","doi-asserted-by":"publisher","unstructured":"Zang R, Zhu J, Shi T, et al. A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1\/SGOG-OV2. J Clin Oncol. 2020;38(15_suppl):6001. https:\/\/doi.org\/10.1200\/jco.2020.38.15_suppl.6001","DOI":"10.1200\/jco.2020.38.15_suppl.6001"},{"issue":"7353","key":"9366_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"D Bell","year":"2011","unstructured":"13. Bell D, Berchuck A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615. https:\/\/doi.org\/10.1038\/nature10166","journal-title":"Nature."},{"issue":"1","key":"9366_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-5235-3","volume":"19","author":"DP Cotrim","year":"2019","unstructured":"Cotrim DP, Ribeiro ARG, Paix\u00e3o D, et al. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil. BMC Cancer. 2019;19(1):1\u20139. https:\/\/doi.org\/10.1186\/s12885-018-5235-3","journal-title":"BMC Cancer."},{"issue":"4","key":"9366_CR15","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","volume":"2","author":"BM Norquist","year":"2016","unstructured":"Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2(4):482\u2013490. https:\/\/doi.org\/10.1001\/jamaoncol.2015.5495","journal-title":"JAMA Oncol."},{"issue":"10","key":"9366_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0186043","volume":"12","author":"P Harter","year":"2017","unstructured":"Harter P, Hauke J, Heitz F, et al. Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS One. 2017;12(10):1\u201312. https:\/\/doi.org\/10.1371\/journal.pone.0186043","journal-title":"PLoS One."},{"issue":"1","key":"9366_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2966-x","volume":"16","author":"S Maistro","year":"2016","unstructured":"Maistro S, Teixeira N, Encinas G, et al. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil. BMC Cancer. 2016;16(1):1\u20138. https:\/\/doi.org\/10.1186\/s12885-016-2966-x","journal-title":"BMC Cancer."},{"issue":"4","key":"9366_CR18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jama.2012.20","volume":"307","author":"KL Bolton","year":"2012","unstructured":"Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012;307(4):382\u2013390. https:\/\/doi.org\/10.1001\/jama.2012.20","journal-title":"JAMA."},{"issue":"21","key":"9366_CR19","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J Clin Oncol. 2012;30(21):2654\u20132663. https:\/\/doi.org\/10.1200\/jco.2011.39.8545","journal-title":"J Clin Oncol."},{"issue":"2","key":"9366_CR20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ygyno.2019.02.022","volume":"153","author":"O Lavie","year":"2019","unstructured":"Lavie O, Chetrit A, Novikov I, Sadetzki S. Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1\/2 mutations\u2014the National Israeli Study of Ovarian Cancer. Gynecol Oncol. 2019;153(2):320\u2013325. https:\/\/doi.org\/10.1016\/j.ygyno.2019.02.022","journal-title":"Gynecol Oncol."},{"issue":"12","key":"9366_CR21","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1245\/s10434-018-6700-6","volume":"25","author":"C Marchetti","year":"2018","unstructured":"Marchetti C, De Leo R, Musella A, et al. BRCA Mutation status to personalize management of recurrent ovarian cancer: a multicenter study. Ann Surg Oncol. 2018;25(12):3701\u20133708. https:\/\/doi.org\/10.1245\/s10434-018-6700-6","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"9366_CR22","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ygyno.2019.09.020","volume":"155","author":"C Marchetti","year":"2019","unstructured":"Marchetti C, Rosati A, Scaletta G, et al. Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study. Gynecol Oncol. 2019;155(3):400\u2013405. https:\/\/doi.org\/10.1016\/j.ygyno.2019.09.020","journal-title":"Gynecol Oncol"},{"issue":"26","key":"9366_CR23","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495-2505. https:\/\/doi.org\/10.1056\/nejmoa1810858","journal-title":"N Engl J Med."},{"issue":"25","key":"9366_CR24","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416\u20132428. https:\/\/doi.org\/10.1056\/nejmoa1911361","journal-title":"N Engl J Med."},{"issue":"25","key":"9366_CR25","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391\u20132402. https:\/\/doi.org\/10.1056\/nejmoa1910962","journal-title":"N Engl J Med."},{"issue":"2","key":"9366_CR26","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ygyno.2012.05.001","volume":"126","author":"DM Hyman","year":"2012","unstructured":"Hyman DM, Long KC, Tanner EJ, et al. Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. Gynecol Oncol. 2012;126(2):224\u2013228. https:\/\/doi.org\/10.1016\/j.ygyno.2012.05.001","journal-title":"Gynecol Oncol."},{"issue":"3","key":"9366_CR27","doi-asserted-by":"publisher","first-page":"334.e1","DOI":"10.1016\/j.ajog.2017.05.036","volume":"217","author":"M Petrillo","year":"2017","unstructured":"Petrillo M, Marchetti C, De Leo R, et al. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Am J Obstet Gynecol. 2017;217(3):334.e1\u2013334.e9. https:\/\/doi.org\/10.1016\/j.ajog.2017.05.036","journal-title":"Am J Obstet Gynecol."},{"issue":"5","key":"9366_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/OGX.0000000000000320","volume":"71","author":"Z Liu","year":"2016","unstructured":"Liu Z, Beach JA, Agadjanian H, et al. Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Obstet Gynecol Surv. 2016;71(5):285\u2013286. https:\/\/doi.org\/10.1097\/ogx.0000000000000320","journal-title":"Obstet Gynecol Surv."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09366-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-09366-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09366-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T13:21:18Z","timestamp":1623072078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-09366-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,21]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["9366"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-09366-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,21]]},"assertion":[{"value":"14 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}